In the DAPA-CKD study [79], among patients with an eGFR of 25 to 75 mL/min/1.73 m2 and an urinary albumin-to-creatinine ratio of 200 to 5000 mg/g, with or without T2DM, dapagliflozin reduced CKD worsening, defined as the composite of a sustained decline in the eGFR of at least 50%, end-stage kidney disease, or death from renal or CV causes by 39% compared to a placebo when added to standard treatment, with an NNT of 19 to prevent 1 event of primary outcome after a median follow-up of 2.4 years (HR 0.61; 95% CI: 0.51–0.72; p < 0.001). This evidence concerns the gene ALB and type 2 diabetes mellitus.